Ovarian cancer is the gynecological malignancy with the highest death rate in Europe. There has been significant improvement in management due to better surgery and chemotherapy but this is inadequately translated into clinical practice across Europe.

Most ovarian cancer patients will relapse and die due tumor progression. There is optimism that the development of novel targeted therapies will lead to substantially better clinical outcome. No predictive markers have been identified to select the patients who will benefit from this strategy, one of the reasons being the absence of systematic linkage between clinical and translational studies.

To improve the current and future management in ovarian cancer we established the European Network for Translational Research in Ovarian Cancer (EUTROC) to bring the complex matrix into a single multi-disciplinary, trans-national framework for ovarian cancer.

EUTROC will define and give direction to the clinical, scientific and technological unmet needs, thereafter performing joint activities such as a European wide tumour bank, common technological platform, a roadmap for the identification and prioritization of suitable biomarkers.

EUTROC will shorten the path between basic research discoveries and clinical trials development and implementation.

Our network includes institutions having a broad experience in clinical and scientific work on ovarian cancer and who have given their unrestricted commitment to improve the long term clinical outcome of our patients within an integrated collaboration across Europe.